Radioimmunoassay for prochlorperazine in human plasma.

Area of Science:

• Analytical Chemistry
• Pharmacology
• Clinical Chemistry

Background:

• Accurate measurement of antiemetic drug plasma concentrations is crucial for pharmacokinetic studies and patient monitoring.
• Existing methods may lack the sensitivity, specificity, or speed required for comprehensive analysis.

Purpose of the Study:

• To develop and validate a sensitive, specific, and rapid radioimmunoassay (RIA) for quantifying prochlorperazine in human plasma.
• To assess the assay's cross-reactivity with common metabolites and co-administered drugs.

Main Methods:

• Development of a radioimmunoassay procedure for prochlorperazine.
• Validation of assay sensitivity, specificity, and precision using plasma samples.
• Testing for cross-reactivity with known metabolites and related drug classes.

Main Results:

• The developed RIA can quantify 31 pg of prochlorperazine in 200 microliters of plasma with a coefficient of variation of approximately 2%.
• The assay demonstrated high specificity, with no significant cross-reactivity observed for tested metabolites (except N-desmethylprochlorperazine) and common co-administered medications.
• The method is rapid and suitable for analyzing small plasma volumes.

Conclusions:

• A highly sensitive and specific RIA for prochlorperazine has been successfully developed.
• This assay is well-suited for pharmacokinetic and bioavailability studies.
• The method is adequate for therapeutic drug monitoring of prochlorperazine in clinical settings.